Angel Invest Boston

Accredited Investors, Join Boston's Leading Angels in Our Syndicates: Learn More About Our Syndicates Brilliant Spanish postdoc, Carlos Castro-González, goes to MIT’s “Magic Wand” lab, and joins a superb international team to address an important medical problem. Leuko, their startup, now has a device and software that can tell when cancer patients are becoming immuno-compromised. Leuko’s product has the potential of saving 4,000 lives and $1.5 billion every year by cutting in half opportunistic infections associated with chemotherapy. Some highlights from this charming conversation with a well-spoken scientist & founder: Carlos Castro-González bio. What Leuko does. How the company came about. How Carlos became an unlikely entrepreneur. MIT’s Martha Gray Lab, often called the “Magic Wand” lab building a new approach to applying technology to real-world medical problems. What the device and software actually do. Potential impact. Who might pay for this product? How much money and time will it take to get